24/7 Market News Snapshot 14 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)
DENVER, Colo., 14 May, 2025 (www.247marketnews.com) – (NASDAQ:CING) are discussed in this article.
Cingulate Inc. (NASDAQ:CING) is experiencing notable trading activity, with shares opening at $3.95 and currently priced at $4.315, marking a substantial increase of approximately 10.36% from the prior close of $3.91. The heightened trading volume of 519.08K indicates a surge in investor interest, suggesting a robust bullish trend. The stock’s movement above previous resistance levels could attract additional buying pressure, and maintaining a price above $4.00 may further solidify this upward trajectory. Market participants are encouraged to monitor key support levels and volume changes to evaluate potential price fluctuations in the upcoming sessions.
In addition to its positive market performance, Cingulate has announced crucial pre-New Drug Application (NDA) feedback from the U.S. Food and Drug Administration (FDA) concerning its lead product, CTx-1301 (dexmethylphenidate). This promising therapeutic candidate is aimed at addressing Attention Deficit/Hyperactivity Disorder (ADHD) and is on schedule for NDA submission this summer. Cingulate’s Chairman and CEO, Shane J. Schaffer, expressed optimism about the constructive feedback received from the FDA, emphasizing that the insights provided align with the company’s submission timeline.
CTx-1301 aims to fill a significant gap in ADHD treatment by offering a first-of-its-kind once-daily stimulant medication with all-day efficacy. Utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) technology, the drug delivers three distinct releases of medication throughout the day, thus optimizing treatment outcomes for patients. Given that over 20 million individuals in the U.S. are diagnosed with ADHD, many of whom remain inadequately treated, the demand for effective and innovative solutions is pressing.
Cingulate intends to utilize its PTR technology to expand its clinical pipeline and pursue additional therapeutic avenues beyond ADHD. This strategic direction underscores the company’s dedication to enhancing patient care through advanced drug delivery methods, while also positioning it to potentially transform treatment paradigms in the future.
Related news for (CING)
- Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)
- 24/7 Market News Snapshot 20 May, 2025 – Cingulate Inc. Common Stock (NASDAQ:CING)
- Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
- FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301